Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Change in number of shares and votes in Alligator Bioscience AB
During April 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has decreased as a result ...
Exercise price determined for the exercise of warrants series TO 12 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience AB reports financial results for Q1 2025 and provides a business update
24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab—three times higher than chemotherapy alone FDA alignment secure ...
Alligator Bioscience announces initiation of HLX22 Phase 2 trial in breast cancer by Shanghai Henlius Biotech, Inc.
Lund, Sweden – 23 April 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Shanghai Henlius Biotech, Inc ...
Notice of annual general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the annual general meeting to be held on Wednesday 7 May 2 ...
Alligator Bioscience determines record date for reverse share split of ordinary shares and reminds of the recalculation of warrants
The board of directors of Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) has resolved that the re ...
Change in number of shares and votes in Alligator Bioscience AB
During March 2025, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result ...
Alligator Bioscience publishes Annual Report for 2024
Lund, Sweden, 27 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2024, as well ...